Company intelligence / Profile preview

Cellivery Therapeutics, Inc.

Seoul, Seoul, South Koreacellivery.com ↗

Ownership: Private
Employees: ~4
Development stage: Preclinical

Overview

The company has been delisted from Kosdaq in March 2025 following financial irregularities and audit rejections. Its share price collapsed by 99% on its final trading day. The company faced accusations of corporate deception and executive malfeasance, with its R&D budget dwindling to just 3 million won by 2023[6].

Therapeutic areas: OncologyEndocrinologyRare DiseasesNeurology
Modalities: Protein drugsSynthetic peptideStem cell therapyASOCRISPR/Cas9
Industry: Biotech

Drug pipeline

5 assets

iCP-NI

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Cellivery Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellivery Therapeutics, Inc..

Explore the full profile